Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Operating Margin: 2009-2025

Historic Operating Margin for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to -11.33%.

  • Myriad Genetics' Operating Margin fell 195.00% to -11.33% in Q3 2025 from the same period last year, while for Sep 2025 it was -50.95%, marking a year-over-year decrease of 3689.00%. This contributed to the annual value of -14.74% for FY2024, which is 1943.00% up from last year.
  • Myriad Genetics' Operating Margin amounted to -11.33% in Q3 2025, which was up 92.67% from -154.48% recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Operating Margin registered a high of -9.38% during Q3 2024, and its lowest value of -154.48% during Q2 2025.
  • Over the past 3 years, Myriad Genetics' median Operating Margin value was -17.26% (recorded in 2024), while the average stood at -34.33%.
  • Its Operating Margin has fluctuated over the past 5 years, first surged by 6,230bps in 2021, then slumped by 13,722bps in 2025.
  • Quarterly analysis of 5 years shows Myriad Genetics' Operating Margin stood at -26.80% in 2021, then crashed by 256bps to -29.36% in 2022, then skyrocketed by 1,339bps to -15.97% in 2023, then tumbled by 255bps to -18.52% in 2024, then crashed by 195bps to -11.33% in 2025.
  • Its last three reported values are -11.33% in Q3 2025, -154.48% for Q2 2025, and -14.80% during Q1 2025.